A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs AMG 714 (Primary)
- Indications Coeliac disease
- Focus Therapeutic Use
- Sponsors Celimmune
- 01 Apr 2017 This trial was completed in Finland, according to European Clinical Trials Database.
- 11 Dec 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2017.
- 11 Dec 2016 Status changed from recruiting to active, no longer recruiting.